We investigate how the confluence of technologies can lead to radical innovation, thus creating opportunities at the firm and industry levels. To do so, we conduct a detailed examination of the development of the transistor and of two nanobiotechnology drugs – Doxil® and Zevalin® – from an innovation management perspective. We argue that three innovation management strategies are central to the development of radical innovation from the confluence of technologies, namely: importing ideas from broad networks, creating environments which allow for deep collaboration, and technology-market matching.

Description:

This is the final author version (accepted manuscript copy following peer review).

Language:

English

Document type:

Article

Rights:

You are free to copy, distribute and transmit this work under the following conditions: You must give attribution to the work (but not in any way that suggests that the author endorses you or your use of the work); You may not use this work for commercial purposes; You may not alter, transform, or build upon this work. Any further uses require the permission of the rights holder (or author if no rights holder is listed). These rights are based on the Creative Commons Attribution-NonCommercial-NoDerivatives License.